VIDEO: No agreement on using measurable residual disease to guide AML therapy

ByRichard M. Stone, MD

ByCory Perla

Fact checked byMindy Valcarcel, MS

NEW ORLEANS — In this video perspective, Richard M. Stone, MD, discusses research presented at ASH Annual Meeting and Exhibition looking at the use of measurable residual disease to guide treatment of patients with acute myeloid leukemia.

"This is still a bone of contention between our European colleagues who recommend MRD monitoring and intervention should it return positive, and myself and my American colleagues who are still unsure of the overall clinical benefit of doing that," Stone, professor of medicine at Harvard Medical school and director of translation research in the adult leukemia program at Dana Farber Institute, said.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interviews

Disclosures: Stone reports serving in consultancy roles for AbbVie, Astellas, Bristol Myers Squibb, BerGenBio, Boston Pharmaceuticals, Elevate Bio, Epizyme, Foghorn Therapeutics, GEMoaB, GSK, Innate, Janssen, Jazz, Kura Oncology, Novartis, OncoNova, Syndax, Syntrix and Syros.

Take Homes in Leukemia

Read more

VIDEO: No agreement on using measurable residual disease to guide AML therapy

Related Content